Novartis says court upholds validity of Gilenya dosage regimen patent

Published by

Swiss pharmaceutical maker Novartis said a US court has upheld a patented dosing regime for a multiple schlerosis drug, in a move that initially protects the drug from generic copies reaching the market. The US Court of Appeals for the Federal Circuit has issued its decision upholding the validity of the US patent covering a dosing regimen for Gilenya, the company said. With the decision, Novartis said it expects no generic versions of Gilenya in the US market for at least the next two years. In August 2020, the US Federal District Court for the District of Delaware issued a permanent injuncti…

Read More

Leave a Reply

Your email address will not be published. Required fields are marked *